GHP NewsLatest Science OspA-Based 6 valent Lyme vaccine shows >70% efficacy in phase 3 VALOR trial across individuals aged 5 years and older Pfizer and Valneva announced topline Phase 3 VALOR data for their investigational 6‑valent OspA-based Lyme disease vaccine candidate PF‑07307405 (LB6V), reporting more than 70% efficacy in preventing Lyme disease in... 2 April, 20264 min read